CDY Chart, page-131

I tipped this stock on STT yesterday...A fundamental tip....thought appropriate to re post it here

Post #: 23787702

STTCOMP CDY FA Long


- CEO aggressively buying on market
- 2nd Qtr revenue up 98% compared to same period last year, with recent launch into USA being potential cash flow positive catalyst next reporting.
- Shares on Issue- 1,063,867,011 9
- Technical's saying heavy accumulation and free float is being decimated
- Royalty income from MK
- Cash Position  A$5.3 million
- Dr David King  Chairman an experienced independent chairman with expertise in high growth companies, has a track record in building business ventures and developing them into attractive takeover targets.


Cellmid is an Australian life sciences accelerator with lead programs in multiple disease indications.  The company holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.

FGF-S- Hair Growth
Évolis is a range of TGA listed hair growth products, the result of over 12 years of research and development. The ingredients in Évolis have been extensively tested for safety and efficacy.

The grass roots and spent marketing campaign is impressive, and it's the first hair treatment product to come onto the market in many many years...recently launched into the lucrative USA market with Mens Health USA naming it in their top 10 grooming products. Dare I say the sales from Women wanting thicker hair will dwarf those by men wanting more.

http://www.menshealth.com/style/november-grooming-must-haves/slide/2

In independent clinical trials 74% of the study participants have had increased hair growth and reduced hair loss*. To find out more and/or purchase please visit www.evolisproducts.com.au



Midkaine

Extensively validated as a cancer biomarker, midkine has three distinct advantages over many current biomarkers used to manage disease:

• • Midkine is elevated very early in disease,  often well before any symptoms are apparent
  • Midkine is elevated in many types of cancer, giving midkine broad diagnostic potential
  • Midkine is readily measured in the non-invasive biofluids of blood and urine, and does not require a biopsy for measurement

"Collaborative pre-clinical (animal) studies carried out in Spain suggest that when combined with medical cannabis, the midkines halt the spread of an aggressive brain cancer called glioblastoma."

http://www.cellmid.com.au/SiteMedia...dkine antibodies show anti-tumor activity.pdf

http://www.biotechdaily.com.au/media/Dr Boreham/MM Feb 3 2017a.pdf



Lyramid received $146,586 income from royalties and sales of its MK diagnostic kit (MK ELISA).
Pacific Edge licensed MK as one of the biomarkers in their bladder cancer diagnostic test (CxBladder®) in 2010. During the half year ended 31 December 2016 Pacific Edge paid to the Consolidated Entity $92,421 in royalties, up 50% from the same period last year